

## **Ganymed acquires ImmuGenics AG and In-licenses Technology from Imperial College London**

Mainz, December 1, 2003

Ganymed Pharmaceuticals AG, an independent biotechnology company that identifies and validates antigen targets to improve therapeutics for life threatening diseases, today announced that it completed the acquisition of 100% of the outstanding stock of ImmuGenics AG and executed an agreement to in-license exclusively certain intellectual property from Imperial College London.

ImmuGenics, based in Mainz, Germany, is focused on the development of immunological effective therapeutics against cancer. In early preclinical experiments, ImmuGenics' highly specific T Cell Receptors ("TCR") showed strong reactivity against a variety of cancer cells including leukaemia cells, without significant side-effects. Simultaneously with the acquisition of ImmuGenics, Ganymed in-licensed exclusively from Imperial certain patents covering the use of TCR Therapy Technologies and the production of TCR, which strongly support the ImmuGenics technology.

"I am pleased that we have been successful in completing these transactions" said James A. Ratigan, CEO of Ganymed. "The T Cell Receptor technology that ImmuGenics has developed will prove to be complementary to our core technology, specifically in the area of oncology, and the licensed patent from Imperial is critical to our fully developing the T Cell Receptor technology".

Ganymed Pharmaceuticals AG is an independent biotechnology company based in Mainz, Germany. Ganymed uses its proprietary technology to rapidly discover, identify and validate highly selective, disease specific cell-surface and intra-cellular antigens to accelerate the commercialization of highly effective therapeutics, initially in cancer, and also in the areas of both infectious and autoimmune diseases. Ganymed intends to become the preferred partner for pharmaceutical and biotechnology companies that develop monoclonal antibodies, small molecule compounds, vaccines, and diagnostic tools.

For further inquiries / contact:

### **GANYMED Pharmaceuticals AG**

James A. Ratigan, CEO  
Freiligrathstrasse 12  
D-55131 Mainz  
Germany

phone: (+49) 6131 / 1440 100  
fax: (+49) 6131 / 1440 111

[info@ganymed-pharmaceuticals.com](mailto:info@ganymed-pharmaceuticals.com)